Oxford Biomedica

Oxford Biomedica, a UK gene and cell therapy company, has announced that its non-executive director, Paul Blake, will become Chief Development Officer on September 1.

Blake has been a member of the company’s Board of Directors since January 2010, and has a 30-year background in pharmaceutical and biotech companies, including involvement in the development of drugs and vaccines such as Requip, Coreg and Provigil.

Most recently, he was Senior Vice President and Chief Medical Officer of Æterna Zentaris, a global pharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014. He also served on the Board of Memory Pharmaceutical until its purchase by Roche in 2009, and of Protez Pharmaceuticals until its 2008 purchase by Novartis.

He has worked for Cephalon, SmithKline Beecham (later GSK), ICI (later AstraZeneca) and GD Searle.

(Picture Credit: Oxford BioMedica.)